Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location in the United States in 2001 to 2007

Journal of Clinical Microbiology

Volumn 47, Issue 10, 2009, Pages 3185-3190

  Pfaller, M A ^a,b   Messer, S A ^a   Hollis, R J ^a   Boyken, L ^a   Tendolkar, S ^a   Kroeger, J ^a   Diekema, D J ^a  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIDULAFUNGIN; CASPOFUNGIN; FLUCONAZOLE; MICAFUNGIN; VORICONAZOLE;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ARTICLE; BLOODSTREAM INFECTION; CANDIDA GLABRATA; CHILD; CONTROLLED STUDY; FUNGAL STRAIN; FUNGUS ISOLATION; GEOGRAPHY; GROUPS BY AGE; HUMAN; INFANT; MAJOR CLINICAL STUDY; NONHUMAN; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; UNITED STATES;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; CANDIDA GLABRATA; CANDIDIASIS; CHILD; CHILD, PRESCHOOL; FEMALE; FLUCONAZOLE; GEOGRAPHY; HUMANS; INFANT; INFANT, NEWBORN; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; UNITED STATES; YOUNG ADULT;

CANDIDA GLABRATA;

EID: 70349635812     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.00946-09     Document Type: Article

References (93)

1. Abi-Said, D., E. Anaissie, O. Uzun, I. Raad, H. Pinzcowski, and S. Vartivarian. 1997. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin. Infect. Dis. 24:1122-1128. (Pubitemid 127774267)
2. Alexander, B. D., W. A. Schell, J. L. Miller, G. D. Long, and J. R. Perfect. 2005. Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole. Transplantation 80:868-871.
3. Almirante, B., D. Rodriquez, B. J. Park, M. Cuenca-Estrella, A. M. Planes, M. Almela, J. Mensa, F. Sanchez, J. Ayats, M. Gimenez, P. Sabolls, S. K. Fridkin, J. Morgan, J. L. Rodriguez-Tudela, D. W. Warnock, A. Pahissa, and the Barcelona Candidemia Project Study Group. 2005. Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J. Clin. Microbiol. 43:1829-1835.
4. Antoniadou, A., H. A. Torres, R. E. Lewis, J. Thornby, G. P. Bodey, J. P. Tarrand, X. Y. Han, K. V. Rolston, A. Safdar, I. I. Raad, and D. P. Kontoyiannis. 2003. Candidemia in a tertiary care center: in vitro susceptibility and its association with outcome of initial antifungal therapy. Medicine 82:309-321. (Pubitemid 37229466)
5. Arendrup, M. C., K. Fuursted, B. Gahrn-Hansen, I. M. Jensen, J. D. Knudsen, B. Lundgren, H. C. Schonheyder, and M. Tvede. 2005. Seminational surveillance of fungemia in Denmark: notably high rates of fungemia and numbers of isolates with reduced azole susceptibility. J. Clin. Microbiol. 43:4434-4440.
6. Arendrup, M. C., K. Fuursted, B. Gahrn-Hansen, H. C. Schonkeyder, J. D. Knudsen, I. M. Jensen, B. Bruun, J. J. Christensen, and H. K. Johansen. 2008. Semi-national surveillance of fungaemia in Denmark 2004-2006: increasing incidence of fungaemia and numbers of isolates with reduced azole susceptibility. Clin. Microbiol. Infect. 14:487-494.
7. Armstrong-James, D. 2007. Invasive Candida species infection: the importance of adequate empirical antifungal therapy. J. Antimicrob. Chemother. 60:459-460.
8. Asmundsdottir, L. R., H. Erlendsdottir, and M. Gottfredsson. 2002. Increasing incidence of candidemia: results from a 20-year nationwide study in Ireland. J. Clin. Microbiol. 40:3489-3492.
9. Baddley, J. W., A. M. Smith, S. A. Moser, and P. G. Pappas. 2001. Trends in frequency and susceptibilities of Candida glabrata bloodstream isolates at a university hospital. Diagn. Microbiol. Infect. Dis. 39:199-201.
10. Baddley, J. W., M. Patel, S. M. Bhavnani, S. A. Moser, and D. R. Andes. 2008. Association of fluconazole pharmacodynamics with mortality in patients with candidemia. Antimicrob. Agents Chemother. 52:3022-3028.
11. Bennett, J. E., K. Izumikawa, and K. A. Marr. 2004. Mechanism of increased fluconazole resistance in Candida glabrata during prophylaxis. Antimicrob. Agents Chemother. 48:1773-1777.
12. Bilgen, H., E. Ozek, V. Korten, et al. 1995. Treatment of systemic neonatal candidiasis with fluconazole. Infection 23:394. (Pubitemid 26007915)
13. Borst, A., M. T. Raimen, D. W. Warnock, et al. 2005. Rapid acquisition of stable azole resistance by Candida glabrata isolates obtained before the clinical introduction of fluconazole. Antimicrob. Agents Chemother. 49:783-787.
14. Boschman, C. R., U. R. Bodnar, M. A. Tornatore, et al. 1998. Thirteen-year evolution of azole resistance in yeast isolates and prevalence of resistant strains carried by cancer patients at a large medical center. Antimicrob. Agents Chemother. 42:734-738.
15. Bougnoux, M. E., G. Kac, P. Aegerter, C. d'Enfert, J. Y. Fagen, and the CandiRea Study Group. 2008. Candidemia and candiduria in critically ill patients admitted to intensive care units in France: incidence, molecular diversity, management and outcome. Intensive Care Med. 34:292-299.
16. Brun, S., T. Berges, P. Poupard, et al. 2004. Mechanism of azole resistance in petite mutants of Candida glabrata. Antimicrob. Agents Chemother. 48:1788-1796.
17. Chow, J. K., Y. Golan, R. Ruthazer, A. W. Karchmer, Y. Carmeli, D. Lichtenberg, V. Chawla, J. Young, and S. Hadley. 2008. Factors associated with candidemia caused by non-albicans Candida species versus Candida albicans in the intensive care unit. Clin. Infect. Dis. 46:1206-1213.
18. Clancy, C. J., V. L. Yu, A. J. Morris, D. R. Snydman, and M. H. Nguyen. 2005. Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia. Antimicrob. Agents Chemother. 49:3171-3177.
19. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A3, 3rd ed. Clinical and Laboratory Standards Institute, Wayne, PA.
20. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts; 3rd informational supplement. M27-S3. Clinical and Laboratory Standards Institute, Wayne, PA.
21. Collins, C. D., G. A. Eschenauer, S. L. Salo, and D. W. Newton. 2007. To test or not to test: a cost minimization analysis of susceptibility testing for patients with documented Candida glabrata fungemias. J. Clin. Microbiol. 45:1884-1888.
22. Cuenca-Estrella, M., D. Rodriquez, B. Almirante, J. Morgan, A. M. Planes, M. Almela, J. Mensa, F. Sanchez, J. Ayats, M. Gimenez, M. Salvado, D. W. Warnock, A. Pahissa, and J. L. Rodriguez-Tudela. 2005. In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance program, Barcelona, Spain, 2002-2003. J. Antimicrob. Chemother. 55:194-199.
23. Cuenca-Estrella, M., A. Gomez-Lopez, E. Mellado, M. J. Buitrago, A. Monzor, and J. L. Rodriguez-Tudela. 2006. Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. Antimicrob. Agents Chemother. 50:917-921.
24. da Matta, D. A., L. P. de Almeida, A. M. Machado, A. C. Azevedo, E. J. U. Kusano, N. F. Travassos, R. Salomao, and A. L. Colombo. 2007. Antifungal susceptibility of 1000 Candida bloodstream isolates to 5 antifungal drugs: results of a multicenter study conducted in Sao Paulo, Brazil, 1995-2003. Diagn. Microbiol. Infect. Dis. 57:399-404.
25. Diekema, D. J., S. A. Messer, A. B. Brueggemann, S. L. Coffman, G. V. Doern, L. A. Herwaldt, and M. A. Pfaller. 2002. Epidemiology of candidemia: 3-year results from the Emerging Infections and the Epidemiology of Iowa Organisms study. J. Clin. Microbiol. 40:1298-1302.
26. Diekema, D. J., S. A. Messer, R. J. Hollis, L. Boyken, S. Tendolkar, J. Kroeger, R. N. Jones, and M. A. Pfaller. 2009. A global evaluation of voriconazole activity tested against recent clinical isolates of Candida spp. Diagn. Microbiol. Infect. Dis. 63:233-236.
27. Driessen, M., J. B. Ellis, P. A. Cooper, et al. 1996. Fluconazole vs. amphotericin B for the treatment of neonatal fungal septicemia: a prospective randomized trial. Pediatr. Infect. Dis. J. 15:1107-1112.
28. Garey, K. W., M. Rege, M. P. Pai, D. E. Mingo, K. J. Suda, R. S. Turpin, and D. T. Bearden. 2006. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin. Infect. Dis. 43:25-31.
29. Garey, K. W., M. P. Pai, K. J. Suda, R. S. Turpin, M. D. Rege, D. E. Mingo, and D. R. Bearden. 2007. Inadequacy of fluconazole dosing in patients with candidemia based on Infectious Disease Society of America (IDSA) guidelines. Pharmacoepidemiol. Drug Safety 16:919-927.
30. Gonzalez, G. M., M. Elizondo, and J. Ayala. 2008. Trends in species distribution and susceptibility of bloodstream isolates of Candida collected in Monterey, Mexico, to seven antifungal agents: results of a 3-year (2004 to 2007) surveillance study. J. Clin. Microbiol. 46:2902-2905.
31. Guery, B. P., M. C. Arendrup, G. Auzinger, E. Azoulay, M. B. Sa, E. M. Johnson, E. Muller, C. Putensen, C. Rotstein, G. Sganga, M. Verditti, R. Z. Crespo, and B. J. Kullberg. 2009. Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients. Part 1. Epidemiology and diagnosis. Intensive Care Med. 35:55-62.
32. Hachem, R., H. Hanna, D. Kontoyiannis, Y. Jiang, and I. Raad. 2008. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer 112:2493-2499.
33. Hajjeh, R. A., A. N. Sofair, L. H. Harrison, G. M. Lyon, B. A. Arthington- Skaggs, S. A. Mirza, M. Phelan, J. Morgan, W. Lee-Yang, M. A. Ciblak, L. E. Benjamin, L. T. Sanza, S. Huie, S. F. Yeo, M. E. Brandt, and D. W. Warnock. 2004. Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 200 in a population-based surveillance program. J. Clin. Microbiol. 42:1519-1527.
34. Hedderwick, S. A., J. Y. Wan, S. F. Bradley, J. A. Sangeorzan, M. S. Terpening, and C. A. Kauffman. 1998. Risk factors for colonization with yeast species in a Veterans Affairs long-term care facility. J. Am. Geriatr. Soc. 46:849-853.
35. Horn, D. L., D. Neofytos, E. J. Anaissie, J. A. Fishman, W. J. Steinbach, A. J. Olyaei, K. A. Marr, M. A. Pfaller, C. H. Chang, and K. M. Webster. 2009. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin. Infect. Dis. 48:1695-1703.
36. Hsueh, P. R., Y. L. Lau, Y. C. Chuang, J. H. Wan, W. K. Huang, J. M. Shyi, J. J. Yan, K. W. Yu, J. J. Wu, W. C. Ko, Y. C. Yang, Y. C. Liu, L. J. Teng, C. Y. Liu, and K. T. Luh. 2005. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003. Antimicrob. Agents Chemother. 49:512-517.
37. Kao, A. S., M. E. Brandt, W. R. Pruitt, L. A. Conn, B. A., Perkins, D. S. Stephens, W. S. Baughman, A. L. Reingold, G. A. Rothrock, M. A. Pfaller, R. W. Pinner, and R. A. Hajjeh. 1999. The epidemiology of candidemia in two United States cities: results of a population-based active surveillance. Clin. Infect. Dis. 29:1164-1170.
38. Kauffman, C. A. 2001. Fungal infections in older adults. Clin. Infect. Dis. 33:550-555.
39. Kaufman, D., R. Boyle, K. C. Hazen, J. T. Patrie, M. Robinson, and L. G. Donowitz. 2001. Fluconazole prophylaxis against fungal colonization and infection in preterm infants. N. Engl. J. Med. 345:1660-1666.
40. Klevay, M. J., E. J. Ernst, J. L. Hollanbaugh, J. G. Miller, M. A. Pfaller, and D. J. Diekema. 2008. Therapy and outcome of Candida glabrata versus Candida albicans bloodstream infection. Diagn. Microbiol. Infect. Dis. 60:273-277.
41. Klevay, M. J., D. L. Horn, D. Neofytos, M. A. Pfaller, and D. J. Diekema. 2009. Initial treatment and outcome of Candida glabrata versus Candida albicans bloodstream infection. Diagn. Microbiol. Infect. Dis. 64:152-157.
42. Laupland, K. B., D. B. Gregson, D. L. Church, T. Ross, and S. Elsayed. 2005. Invasive Candida species infections: a 5 year population-based assessment. J. Antimicrob. Chemother. 56:532-537.
43. Lee, I., N. O. Fishman, T. E. Zaoutis, K. H. Morales, M. G. Weiner, M. Synnestvedt, I. Nachamkin, and E. Lautenbach. 2009. Risk factors for fluconazole- resistant C. glabrata bloodstream infections. Arch. Intern. Med. 169:379-383.
44. Li, L., S. Redding, and A. Dongari-Bagtzoglou. 2007. Candida glabrata, an emerging oral opportunistic pathogen. J. Dent. Res. 86:204-215.
45. Lichtenstein, C., T. H. Nguyen, P. Schemm, T. Hoppe-Tichy, and M. A. Weigand. 2008. Efficacy of caspofungin in invasive candidiasis and candidemia - de-escalation strategy. Mycoses 51(Suppl. 1):35-46.
46. Lockhart, S. R., S. Joly, K. Vargas, J. Swails-Wenger, L. Enger, and D. R. Soll. 1999. Natural defenses against Candida colonization break down in the oral cavities of the elderly. J. Dent. Res. 78:857-868.
47. Magill, S. S., C. Shields, C. L. Sears, M. Choti, and W. G. Merz. 2006. Triazole cross-resistance among Candida spp.: case report, occurrence among bloodstream isolates, and implications for antifungal therapy. J. Clin. Microbiol. 44:529-535.
48. Malani, A., J. Hmoud, L. Chiu, P. L. Carver, A. Bielaczyc, and C. A. Kauffman. 2005. Candida glabrata fungemia: experience in a tertiary care center. Clin. Infect. Dis. 41:975-981.
49. Manzoni, P., I. Stolfi, L. Pugni, et al. 2007. A multicenter, randomized trial of prophylactic fluconazole in preterm neonates. N. Engl. J. Med. 356:2483-2495.
50. Marichal, P., H. Vanden Bossche, F. C. Odds, et al. 1997. Molecular biological characterization of an azole-resistant Candida glabrata isolate. Antimicrob. Agents Chemother. 41:2229-2237.
51. Marr, K. A., K. Seidel, T. C. White, and R. A. Bowden. 2000. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J. Infect. Dis. 181:309-316.
52. Morrell, M., V. J. Fraser, and M. J. Kollef. 2005. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for mortality. Antimicrob. Agents Chemother. 49:3640-3645.
53. Nguyen, M. H., J. E. Peacock, Jr., A. J. Morris, et al. 1996. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am. J. Med. 100:617-623.
54. Ostrosky-Zeichner, L., J. H. Rex, P. G. Pappas, R. J. Hamill, R. A. Lassen, H. W. Horowitz, W. G. Powderly, N. Hyslop, C. A. Kauffman, J. Cleary, J. E. Mangeno, and J. Lee. 2003. Antifungal susceptibility survey of 2000 bloodstream Candida isolates in the United States. Antimicrob. Agents Chemother. 47:3149-3154.
55. Panackal, A. A., J. L. Gribskov, J. F. Staab, K. A. Kirby, M. Rinaldi, and K. A. Marr. 2006. Clinical significance of azole antifungal drug cross-resistance in Candida glabrata. J. Clin. Microbiol. 44:1740-1743.
56. Pappas, P. G. 2008. The patient with candidemia: treatment choices and algorithms. Curr. Fungal Infect. Rep. 2:112-119.
57. Pappas, P. G., C. A. Kauffman, D. Andes, D. K. Benjamin, T. F. Calandra, J. E. Edwards, S. G. Filler, J. F. Fisher, B. J. Kullberg, L. Ostrosky-Zeichner, A. C. Reboli, J. H. Rex, T. J. Walsh, and J. D. Sobel. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48:503-535.
58. Pappas, P. G., J. H. Rex, J. D. Sobel, S. G. Filler, W. E. Dismukes, T. J. Walsh, and J. E. Edwards for the Infectious Diseases Society of America. 2004. Guidelines for the treatment of candidiasis. Clin. Infect. Dis. 38:161-189.
59. Parkins, M. D., D. M. Sabuda, S. Elsayed, and K. B. Laupland. 2007. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. J. Antimicrob. Chemother. 60:613-618.
60. Pasqualotto, A. C., R. A. Zimerman, S. H. Alves, V. R. Aquino, D. Branco, D. Wiltgen, A. do Amaral, R. Cechinel, S. M. Colares, I. G. da Rocha, L. C. Severo, and T. C. T. Sukiennik. 2008. Take control over your fluconazole prescription: the growing importance of Candida glabrata as an agent of candidemia in Brazil. Infect. Control Hosp. Epidemiol. 29:898-899.
61. Perlroth, J., B. Choi, and B. Spellberg. 2007. Nosocomial fungal infections: epidemiology, diagnosis, and treatment. Med. Mycol. 45:321-346.
62. Pfaller, M. A., S. A. Messer, R. J. Hollis, R. N. Jones, G. V. Doern, M. E. Brandt, and R. A. Hajjeh. 1999. Trends in species distribution and susceptibility to fluconazole among blood stream isolates of Candida species in the United States. Diagn. Microbiol. Infect. Dis. 33:217-222.
63. Pfaller, M. A., S. A. Messer, L. Boyken, S. Tendolkar, R. J. Hollis, and D. J. Diekema. 2003. Variation in susceptibility of bloodstream isolates of Candida glabrata to fluconazole according to patient age and geographic location. J. Clin. Microbiol. 41:2176-2179.
64. Pfaller, M. A., S. A. Messer, L. Boyken, S. Tendolkar, R. J. Hollis, and D. J. Diekema. 2004. Geographic variation in the susceptibilities of invasive isolates of Candida glabrata to seven systemically active antifungal agents; a global assessment from the ARTEMIS Antifungal Surveillance Program conducted in 2001 to 2002. J. Clin. Microbiol. 42:3142-3146.
65. Pfaller, M. A., and D. J. Diekema. 2004. Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida. Clin. Microbiol. Infect. 10(Suppl. 1):11-23.
66. Pfaller, M. A., D. J. Diekema, and D. J. Sheehan. 2006. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin. Microbiol. Rev. 19:435-447.
67. Pfaller, M. A., D. J. Diekema, J. H. Rex, A. Espinel-Ingroff, E. M. Johnson, D. Andes, V. Chaturvedi, M. A. Ghannoum, F. C. Odds, M. G. Rinaldi, D. J. Sheehan, P. Troke, T. J. Walsh, and D. W. Warnock. 2006. Correlation of MIC with outcome for Candida species testing against voriconazole: analysis and proposal for interpretive breakpoints. J. Clin. Microbiol. 44:819-826.
68. Pfaller, M. A., and D. J. Diekema. 2007. Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev. 20:133-163.
69. Pfaller, M. A., and D. J. Diekema. 2007. Azole antifungal drug cross-resistance: mechanisms, epidemiology, and clinical significance. J. Invasive Fungal Infect. 1:74-92.
70. Pfaller, M. A., S. A. Messer, L. Boyken, C. Rice, S. Tendolkar, R. J. Hollis, and D. J. Diekema. 2007. Use of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13,338 clinical isolates of Candida spp. tested by Clinical and Laboratory Standards Institute-recommended broth microdilution methods. J. Clin. Microbiol. 45:70-75.
71. Pfaller, M. A., D. J. Diekema, D. L. Gibbs, V. A. Newell, J. F. Meis, I. M. Gould, W. Fu, A. L. Colombo, and E. Rodriguez-Noriega for the Global Antifungal Surveillance Study. 2007. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2005: an 8.5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J. Clin. Microbiol. 45:1735-1745.
72. Pfaller, M. A., L. Boyken, R. J. Hollis, J. Kroeger, S. A. Messer, S. Tendolkar, and D. J. Diekema. 2008. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J. Clin. Microbiol. 46:150-156.
73. Pfaller, M. A., D. J. Diekema, L. Ostrosky-Zeichner, J. H. Rex, B. D. Alexander, D. Andes, S. D. Brown, V. Chaturvedi, M. A. Ghannoum, L. L. Knapp, D. J. Sheehan, and T. J. Walsh. 2008. Correlation with MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J. Clin. Microbiol. 46:2620-2629.
74. Poikonen, E., O. Lyytikainen, V. J. Arttila, and P. Ruutu. 2003. Candidemia in Finland, 1995-1999. Emerg. Infect. Dis. 9:352-356.
75. Qi, Q. G., T. Hu, and X. O. Zhou. 2005. Frequency, species and molecular characterization of oral Candida in hosts of different age in China. J. Oral Pathol. Med. 34:352-356.
76. Redding, S. W., W. R. Kirkpatrick, B. J. Coco, L. Sadkowski, A. W. Fothergill, M. G. Rinaldi, T. Y. Eng, and T. G. Patterson. 2002. Candida glabrata oropharyngeal candidiasis in patients receiving radiation treatment for head and neck cancer. J. Clin. Microbiol. 40:1879-1881.
77. Redding, S. W., W. R. Kirkpatrick, S. Sarille, B. J. Coco, W. White, A. Fothergill, M. Rinaldi, T. Eng, T. F. Patterson, and J. Lopez-Ribot. 2003. Multiple patterns of resistance to fluconazole in Candida glabrata isolates from a patient with oropharyngeal candidiasis receiving head and neck radiation. J. Clin. Microbiol. 41:619-622.
78. Rees, J. R., R. W. Pinner, R. A. Hajjeh, M. E. Brandt, and A. L. Reingold. 1998. The epidemiological features of invasive mycotic infections in the San Francisco Bay area, 1992-1993: results of a population-based laboratory active surveillance. Clin. Infect. Dis. 27:1138-1147.
79. Rex, J. H., and M. A. Pfaller. 2002. Has antifungal susceptibility testing come of age? Clin. Infect. Dis. 35:982-989.
80. Riddell, J., IV, and C. A. Kauffman. 2008. The evolution of resistant Candida species in cancer centers: implications for treatment and prophylaxis. Cancer 112:2334-2337.
81. Ruan, S. Y., L. N. Lee, J. S. Jerng, C. J. Yu, and P. R. Hsueh. 2008. Candida glabrata fungaemia in intensive care units. Clin. Microbiol. Infect. 14:136-140.
82. Sandven, P., L. Bevanger, A. Digranes, H. H. Haukland, T. Mannsaker, P. Gaustad, and the Norwegian Yeast Study Group. 2006. Candidemia in Norway (1991 to 2003): results from a nationwide study. J. Clin. Microbiol. 44:1977-1981.
83. Sanglard, D., F. Ischer, D. Calabrese, et al. 1999. The ATP binding cassette transporter gene CgCDR1 from Candida glabrata is involved in the resistance of clinical isolates to azole antifungal agents. Antimicrob. Agents Chemother. 43:2753-2765.
84. Sanguinetti, M., B. Posteraro, B. Fiori, S. Ranno, R. Torelli, and G. Fadda. 2005. Mechanisms of azole resistance in clinical isolates of Candida glabrata collected during a hospital survey of antifungal resistance. Antimicrob. Agents Chemother. 49:668-679.
85. Sendid, B., A. Cotteau, N. Francois, A. D'Haveloose, A. Standaert, D. Camus, and D. Poulain. 2006. Candidaemia and antifungal therapy in a French university hospital: rough trends over a decade and possible links. BMC Infect. Dis. 6:80-89.
86. Spellberg, B. J., S. G. Filler, and J. E. Edwards, Jr. 2006. Current treatment strategies for disseminated candidiasis. Clin. Infect. Dis. 42:244-251.
87. Tan, T. Y., A. L. Tan, N. W. S. Tee, and L. S. Y. Ng. 2008. A retrospective analysis of antifungal susceptibilities of Candida bloodstream isolates from Singapore hospitals. Ann. Acad. Med. Singapore 37:835-840.
88. Tortorano, A. M., C. Kibbler, J. Peman, H. Bernhandt, L. Klingspor, and R. Grillot. 2006. Candidaemia in Europe: epidemiology and resistance. Int. J. Antimicrob. Agents 27:359-366.
89. Trick, W. E., S. K. Fridkin, J. R. Edwards, R. A. Hajjeh, R. P. Gaynes, and the National Nosocomial Infections Surveillance System Hospitals. 2002. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin. Infect. Dis. 35:622-630.
90. Wilson, A. G., S. T. Micek, and D. J. Ritchie. 2005. A retrospective evaluation of fluconazole for the treatment of Candida glabrata fungemia. Clin. Ther. 27:1228-1237.
91. Xess, I., N. Jain, F. Hasan, P. Mandal, and U. Baneyie. 2007. Epidemiology of candidemia in a tertiary care centre of north India: 5-year study. Infection 35:256-259. (Pubitemid 47222273)
92. Yang, Y. L., H. H. Chang, H. J. Lo, and the TSARY Hospitals. 2006. Distribution and antifungal susceptibility of Candida species isolated from different age population in Taiwan. Med. Mycol. 44:237-242.
93. Zilberberg, M. D., A. F. Shorr, and M. H. Kollef. 2008. Secular trends in candidemia-related hospitalization in the United States, 2000-2005. Infect. Control Hosp. Epidmiol. 29:978-980.